» Articles » PMID: 35317101

Mixed Neuroendocrine-nonneuroendocrine Neoplasms of the Gastrointestinal System: An Update

Overview
Specialty Gastroenterology
Date 2022 Mar 23
PMID 35317101
Authors
Affiliations
Soon will be listed here.
Abstract

Mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs) of the digestive tract are a rare heterogeneous group of tumors that present many challenges in terms of diagnosis and treatment. Over the years, the diagnostic criteria, classification, and clinical behavior of these tumors have been the subjects of ongoing debate, and the various changes in their nomenclature have strengthened the challenges associated with MiNENs. This review is performed to provide an understanding of the key factors involved in the evolution of the designation of these tumors as MiNEN, highlight the current diagnostic criteria, summarize the latest data on pathogenesis and provide information on available treatments. Moreover, this work seeks to increase the awareness about these rare neoplasms by presenting the clinicopathological features and prognostic factors that play important roles in their behavior and discussing their different regions of origin in the gastrointestinal system (GIS). Currently, the MiNEN category also includes tumors in the GIS with a nonneuroendocrine component and epithelial tumors other than adenocarcinoma, depending on the organ of origin. Diagnosis is based on the presence of both morphological components in more than 30% of the tumor. However, this value needs to be reconfirmed with further studies and may be a limiting factor in the diagnosis of MiNEN by biopsy. Furthermore, available clinicopathological data suggest that the inclusion of amphicrine tumors in the definition of MiNEN is not supportive and warrants further investigation. The diagnosis of these tumors is not solely based on immunohistochemical findings. They are not hybrid tumors and both components can act independently; thus, careful grading of each component separately is required. In addition to parameters such as the metastatic state of the tumor at the time of diagnosis and the feasibility of surgical resection, the aggressive potential of both components has paramount importance in the choice of treatment. Regardless of the organ of origin within the GIS, almost MiNENs are tumors with poor prognosis and are frequently encountered in the elderly and men. They are most frequently reported in the colorectum, where data from molecular studies indicate a monoclonal origin; however, further studies are required to provide additional support for this origin.

Citing Articles

Critical considerations for the management of gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms and pure neuroendocrine carcinomas.

Pavlidis E, Galanis I, Pavlidis T World J Gastrointest Oncol. 2024; 16(12):4559-4564.

PMID: 39678788 PMC: 11577359. DOI: 10.4251/wjgo.v16.i12.4559.


Mixed neuroendocrine-nonneuroendocrine epithelial neoplasm of muscle invasive bladder cancer: a clinicopathologic case study.

Tran P, Rama Sai P, Prasad C, Do H, Parsa C J Surg Case Rep. 2024; 2024(10):rjae612.

PMID: 39376718 PMC: 11457532. DOI: 10.1093/jscr/rjae612.


Epidemiological, Clinical and Biological Hemogram Features in a Cohort of Neuroendocrine Tumor Patients.

Cimpeanu R, Salmen T, Boldeanu L, Mustata M, Fortofoiu D, Cazacu S Curr Health Sci J. 2024; 50(2):256-266.

PMID: 39371064 PMC: 11447499. DOI: 10.12865/CHSJ.50.02.11.


Pathologic Features of Miscellaneous Foregut Malignancies.

Sharobim M, Matkovic E, Schwalbe M, Matkowskyj K Cancer Treat Res. 2024; 192:49-66.

PMID: 39212915 DOI: 10.1007/978-3-031-61238-1_3.


Unveiling the Rarity: A Case of a Mixed Neuroendocrine-Non-Neuroendocrine Tumor of the Gastroesophageal Junction.

Alamin F, Sage H, Torres I, Parikh J, Zayat V Cureus. 2024; 16(6):e63141.

PMID: 39055477 PMC: 11272183. DOI: 10.7759/cureus.63141.


References
1.
Furlan D, Sahnane N, Mazzoni M, Pastorino R, Carnevali I, Stefanoli M . Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Arch. 2012; 462(1):47-56. DOI: 10.1007/s00428-012-1348-2. View

2.
Koppert L, Wijnhoven B, Tilanus H, Stijnen T, van Dekken H, Dinjens W . Neuroendocrine in Barrett's mucosa and adenocarcinomas of the gastroesophageal junction. Int J Surg Pathol. 2004; 12(2):117-25. DOI: 10.1177/106689690401200204. View

3.
Kinugasa H, Hiraoka S, Oka S, Okada H . Ulcerative Colitis Associated with a Mixed Neuroendocrine-non-neuroendocrine Neoplasm. Intern Med. 2020; 59(16):2085-2086. PMC: 7492109. DOI: 10.2169/internalmedicine.4609-20. View

4.
Adsay V, Ohike N, Tajiri T, Kim G, Krasinskas A, Balci S . Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases. Am J Surg Pathol. 2012; 36(11):1592-608. DOI: 10.1097/PAS.0b013e31826399d8. View

5.
Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P . Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocr Relat Cancer. 2018; 25(5):583-593. DOI: 10.1530/ERC-17-0557. View